Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 5;7(8):e14991.
doi: 10.2196/14991.

German Mobile Apps in Rheumatology: Review and Analysis Using the Mobile Application Rating Scale (MARS)

Johannes Knitza  1   2 , Koray Tascilar  1 , Eva-Maria Messner  3 , Marco Meyer  2   4 , Diana Vossen  2   5 , Almut Pulla  2   5 , Philipp Bosch  6 , Julia Kittler  1   2 , Arnd Kleyer  1   2 , Philipp Sewerin  2   7 , Johanna Mucke  2   7 , Isabell Haase  2   7 , David Simon  1   2 , Martin Krusche  2   8
Affiliations

German Mobile Apps in Rheumatology: Review and Analysis Using the Mobile Application Rating Scale (MARS)

Johannes Knitza et al. JMIR Mhealth Uhealth. .

Abstract

Background: Chronic rheumatic diseases need long-term treatment and professional supervision. Mobile apps promise to improve the lives of patients and physicians. In routine practice, however, rheumatology apps are largely unknown and little is known about their quality and safety.

Objective: The aim of this study was to provide an overview of mobile rheumatology apps currently available in German app stores, evaluate app quality using the Mobile Application Rating Scale (MARS), and compile brief, ready-to-use descriptions for patients and rheumatologists.

Methods: The German App Store and Google Play store were systematically searched to identify German rheumatology mobile apps for patient and physician use. MARS was used to independently assess app quality by 8 physicians, 4 using Android and 4 using iOS smartphones. Apps were randomly assigned so that 4 apps were rated by all raters and the remaining apps were rated by two Android and two iOS users. Furthermore, brief app descriptions including app developers, app categories, and features were compiled to inform potential users and developers.

Results: In total, 128 and 63 apps were identified in the German Google Play and App Store, respectively. After removing duplicates and only including apps that were available in both stores, 28 apps remained. Sixteen apps met the inclusion criteria, which were (1) German language, (2) availability in both app stores, (3) targeting patients or physicians as users, and (4) clearly including rheumatology or rheumatic diseases as subject matter. Exclusion criteria were (1) congress apps and (2) company apps with advertisements. Nine apps addressed patients and 7 apps addressed physicians. No clinical studies to support the effectiveness and safety of apps could be found. Pharmaceutical companies were the main developers of two apps. Rheuma Auszeit was the only app mainly developed by a patient organization. This app had the highest overall MARS score (4.19/5). Three out of 9 patient apps featured validated questionnaires. The median overall MARS score was 3.85/5, ranging from 2.81/5 to 4.19/5. One patient-targeted and one physician-targeted app had MARS scores >4/5. No significant rater gender or platform (iOS/Android) differences could be observed. The overall correlation between app store ratings and MARS scores was low and inconsistent between platforms.

Conclusions: To our knowledge, this is the first study that systematically identified and evaluated mobile apps in rheumatology for patients and physicians available in German app stores. We found a lack of supporting clinical studies, use of validated questionnaires, and involvement of academic developers. Overall app quality was heterogeneous. To create high-quality apps, closer cooperation led by patients and physicians is vital.

Keywords: Mobile Application Rating Scale; eHealth; mHealth; mobile apps; rheumatology.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
App selection process flowchart.
Figure 2
Figure 2
Mobile Application Rating Scale overall ratings of included apps.
Figure 3
Figure 3
Mobile Application Rating Scale section item scores by section and app.
Figure 4
Figure 4
Rater deviations in item scores.
See this image and copyright information in PMC

References

    1. Kataria S, Ravindran V. Digital health: a new dimension in rheumatology patient care. Rheumatol Int. 2018 Nov;38(11):1949–1957. doi: 10.1007/s00296-018-4037-x.10.1007/s00296-018-4037-x - DOI - PubMed
    1. Burmester G. Rheumatology 4.0: big data, wearables and diagnosis by computer. Ann Rheum Dis. 2018 Jul;77(7):963–965. doi: 10.1136/annrheumdis-2017-212888. http://ard.bmj.com/cgi/pmidlookup?view=long&pmid=29802224 annrheumdis-2017-212888 - DOI - PMC - PubMed
    1. Ronicke S, Hirsch MC, Türk E, Larionov K, Tientcheu D, Wagner AD. Can a decision support system accelerate rare disease diagnosis? Evaluating the potential impact of Ada DX in a retrospective study. Orphanet J Rare Dis. 2019 Dec 21;14(1):69. doi: 10.1186/s13023-019-1040-6. https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1040-6 10.1186/s13023-019-1040-6 - DOI - PMC - PubMed
    1. Gossec L, Guyard F, Leroy D, Lafargue T, Seiler M, Jacquemin C, Molto A, Sellam J, Foltz V, Gandjbakhch F, Hudry C, Mitrovic S, Fautrel B, Servy H. Detection of flares by decrease in physical activity, collected using wearable activity trackers, in rheumatoid arthritis or axial spondyloarthritis: an application of machine-learning analyses in rheumatology. Arthritis Care Res (Hoboken) 2018 Sep 22; doi: 10.1002/acr.23768. - DOI - PubMed
    1. Knitza J, Vossen D, Geffken I, Krusche M, Meyer M, Sewerin P, Kleyer A, Hueber AJ. [Use of medical apps and online platforms among German rheumatologists: results of the 2016 and 2018 DGRh conference surveys and research conducted by rheumadocs] Z Rheumatol. 2018 Dec 12; doi: 10.1007/s00393-018-0578-3.10.1007/s00393-018-0578-3 - DOI - PubMed

Publication types

MeSH terms